Tamsin Lacourte’s Post

𝐏𝐥𝐚𝐬𝐦𝐢𝐝 𝐃𝐍𝐀 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 : 𝐀 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰(𝐞-𝐏𝐃𝐅 𝐆𝐮𝐢𝐝𝐞) 𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐞-𝐏𝐃𝐅 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭 — https://lnkd.in/dP3BbSD7 The global #plasmid #DNA contract manufacturing market size is expected to reach USD 1,117.5 million by 2030, registering a CAGR of 19.3%, according to a new report by Grand View Research, Inc. The growing popularity of cell & gene therapy, prevalence of chronic diseases is increasing and plasmid DNA has a wide range of uses in the healthcare sector are the key factors driving the growth of the market. #gvr #marketresearch #globalmarket #marketindustry #research

The discovery of microRNA has led to groundbreaking discoveries on gene expression, cell/organism development, and disease progression. In short, it is a discovery worth yesterday’s announced #NobelPrize for #Medicine of #2024. Congratulations to Victor Ambros and Gary Ruvkun for their major impact on #science. 💪 Do you also wish to greatly impact the transfection of (Micro) RNAs? Check out our transfection reagents of #Polyplus. https://lnkd.in/eSpF48h6

🌍🔬 Promising Developments in Cell and Gene Therapy in South and Central America - June 2024 Insights from the recently published regulatory Watchdog report: "A Roadmap for Accelerating Access to Life-Saving Therapies in South and Central America", from the ISCT, International Society for Cell & Gene Therapy. The report includes highlights from the recent IMPACT-ISCT Joint Session held in Santiago, underscoring the critical need for accessible treatments like #CAR-T cells. 🔍 Key highlights: . 96 CGT approvals worldwide, yet none accessible in many countries in the region including #Chile. IMPACT center aims to bridge this gap. . Brazil leads with 6 ATMP approvals, setting a regulatory precedent. . Strategic partnerships with regulatory bodies and Health advocacy groups such as Pro Salud Chile to ensure robust frameworks for therapy access. https://lnkd.in/dsXncmTS #CellTherapy #GeneTherapy #CAR-T #MedicalInnovation #RegulatoryFramework #HealthcareInnovation #IMPACTCenter #ISCT #GlobalHealthcare #ResearchAndDevelopment Maroun khoury

AAV is the leader of gene therapy. But what are it's pros and cons? Let's break it down. Pros: - Current leader in vector-based gene therapy - Payload doesn't integrate into patient DNA (normally) - FDA-approved therapies on the market - Can target specific tissues for precise delivery Cons: - High cost of manufacturing - Small payload size - Good quality at scale is a challenge - Single dose administration due to high immunogenicity (for now) - Liver toxicity concerns (for now) I'm excited to see how recent advances in capsid design will fix these drawbacks. Anything else you'd add? Drop it in the comments. For content that breaks down the science of CGT: Check out #cgt_simplified “Created with BioRender.com” #genetherapy #aav #biotechnology

📢 Unlocking Sterility Solutions for Gene Therapies! 🌟 The article focuses on sterility challenges in cell and gene therapy manufacturing. 🧬 It highlights contamination risks that can compromise product quality. 🔬 Solutions include advanced sterilization techniques and stringent quality control measures. 💡 Collaboration among researchers and manufacturers is crucial for overcoming these obstacles. ✨ Addressing these challenges is essential for advancing effective therapies. #BioprocessUpdates #CellTherapy #GeneTherapy #SterilityChallenges #ManufacturingExcellence #ContaminationControl #QualityAssurance #AdvancedSterilization #BiotechInnovation #ResearchCollaboration #TherapyDevelopment #HealthcareAdvancements #PharmaceuticalManufacturing #LifeSciences #TherapeuticSolutions #Biomanufacturing ▷ Read the full article here: 📎 https://lnkd.in/dChmTNPU

Are you working on developing new gene therapies? Touchlight's innovative MegaBulb DNA might be the solution you've been looking for. This non-viral ssDNA template is setting new standards in CRISPR applications. A recent article by Touchlight’s Senior Scientist Elena Stoyanova, PhD and Associate Director of Research Tom Adie, PhD explores how MegaBulb DNA outperforms traditional HDR templates’ genome repair rates, offering more consistent results. Discover the potential of MegaBulb DNA for your research. Check out our latest publication and join the gene editing revolution: https://lnkd.in/euxV8vmk #genetherapy #pharma #lifesciences #DNA

Researchers at Yale have made a breakthrough in targeting a gene variant associated with autoimmune diseases by identifying a molecule that can bind to it. This discovery opens up new possibilities for developing precision medicine-based therapies that could be effective in treating various autoimmune and inflammatory conditions. By selectively inhibiting the disease-associated gene variant, the potential treatment could offer a more precise and less toxic option compared to current treatments. #AutoimmuneDisease #PrecisionMedicine #InflammatoryConditions #GeneVariant #YaleResearch Read more here: https://lnkd.in/emNi2rqR BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Cell and Gene Therapy in the Asia-Pacific Region https://lnkd.in/ek89D7BS 2 Key Challenges for Access The field of cell and gene therapies (CGTs) holds transformative potential, but it is not without hurdles, especially in the Asia-Pacific (APAC) region. In this update we summarize two key access challenges that CGTs face, distinct from those encountered by traditional therapies – the challenging complexity of manufacturing and delivery, and the ultra-high price tag. We also explore the questions that these challenges raise in the APAC context. Read the update https://lnkd.in/ek89D7BS #MarketAccess #HEOR #WeAreAvalereHealth

Genetic disease knows no borders. Neither should #CRISPR cures. Essential reading in https://lnkd.in/g3dKk9Vn ... showcasing the #yeswecan approach to providing gene therapy cures in India, Brazil, Thailand, and beyond. A key goal of the Innovative Genomics Institute Danaher Corporation for CRISPR Cures https://lnkd.in/gUKZRKRq is to have gene editing follow that example and build Platform approaches to make such cures affordable, manufacturable, and deliverable to patients where the unmet medical need is, and not just where the current GMP suites are. #HealthJustice

Legend Capital君联资本 has invested in the healthcare sector since 2007, building a distinctive and valuable ecosystem. Innostellar serves as a representative example of Legend Capital's ESG investments. Innostellar embraces a strong mission: "To create gene therapy drugs that are affordable for the Chinese people and to restore the healthy lives of patients with genetic diseases and chronic illnesses." This commitment led the company to invent China's first gene therapy drug for inherited retinal degeneration. Throughout its development, Legend Capital has supported Innostellar Biotherapeutics in refining the company's structure, organizational design, strategic planning, and pipeline development, resulting in significant advancements in research and development. Currently, Innostellar has nine active pipelines and is continuously enhancing its research efforts for specific genetic therapies and universal treatments targeting rare diseases in China. #LegendCapital #LCESG #Sustainability #LegendCapital2024ESGReport